Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
ГлавнаяРезультаты поиска
СтатьяИскать документыПерейти к записи. 2017; № 12: 112–117. DOI:10.21518/2079-701X-2017-12-112-117
ИННОВАЦИОННАЯ СТРАТЕГИЯ В ТЕРАПИИ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ
Искать документыПерейти к записи[1]
Аффилированные организации
[1]Искать документыПерейти к записи
Аннотация
undefined.undefinedundefined.undefined
Ключевые слова
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Рубрики Mesh
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Литература

Kentsch M, Otter W. Novel neurohormonal modulators in cardiovascular disorders. The therapeutic potential of endopeptidase inhibitiors. Drugs R D, 1999 Apr, 1(4): 331-338.

Cruden NL, Fox KA, Ludlam CA et al. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension, 2004, 44: 913-918.

Rademaker MT, Charles CJ, Espiner EA et al. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci (Lond), 1996, 91: 283-291.

Wilkinson IB, McEniery CM, Bongaerts KH et al. Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). Br J Clin Pharmacol, 2001, 52: 159-164.

Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med, 1998, 339: 321-328.

Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders. Drugs, 2003, 63: 2185-2202.

Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders. Drugs, 2003, 63: 2185-2202.

Mukoyama M, Nakao K, Obata K. Augmented secretion of brain natriuretic peptide in acute myocardial infarction. Biochem Biophys Res Commun, 1991, 180: 431-436.

Protter AA, Wallace AM, Ferraris VA, Weishaar RE. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens, 1996 May, 9(5): 432-436.

Corti R, Burnett JC, Rouleau JL et al. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation, 2001, 104: 1856-1862.

Mangiafico S, Costello-Boerrigter LC, Andersen IA et al. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. European Heart Journal, 2013, 34: 886-893.

Grantham JA, Borgeson DD, Burnett JC. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. Am J Physiol, 1997, 92: 1077-1083.

Maeda K, Takayoshi T, Wada A et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J, 1998, 135: 825-832.

Muders F, Kromer EP, Griese DP et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J, 1997, 134: 442-449.

Tonne JM, Campbell JM, Cataliotti A et al. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Clin Chem, 2011: 57864-57873.

Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol, 1998, 274: 63-72.

De Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci, 1981, 28: 89-94.

Chen HH, Burnett JC Jr. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol, 1998, 32(Suppl. 3): S22-S28.

Chauhan SD, Hobbs AJ, Ahluwalia A. C-type natriuretic peptide: new candidate for endothelium-derived hyperpolarising factor. Int J Biochem Cell Biol, 2004, 36: 1878-1881.

Ichiki T, Huntley BK, Heublein DM et al. Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation. Clin Chem, 2011, 57: 40-47.

Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation, 2004, 109: 594-600.

Belluardo P, Cataliotti A, Bonaiuto L et al. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol, 2006, 291: H1529-H1535.

Macheret F, Heublein D, Costello-Boerrigter LC et al. Human hypertension is characterized by a lack of activation of the anti-hypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol, 2011, 57: 1386-1395.

Hawkridge AM, Heublein DM, Bergen HR 3rd et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA, 2005, 102: 17442-17447.

Niederkofler EE, Kiernan UA, O’Rear J et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail, 2008, 1: 258-264.

Miller WL, Phelps MA, Wood CM et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail, 2011, 4: 355-360.

Dries DL, Victor RG, Rame J et al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation, 2005, 112: 2403–2410.

Chan JC, Knudson O, Wu F et al. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci USA, 2005, 102: 785-790.

Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis, 2005, 47: 320-332.

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991, 325: 293-302.

Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA, 1995, 273: 1450-1456.

Rouleau JL, Pfeffer MA, Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet, 2000, 356(9230): 615-620.

Packer M, Califf RM, Konstam MA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation, 2002, 106: 920-926.

Kostis JB, Packer M, Black HR et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. American Journal of Hypertension, 2004 February 1, 17(Issue 2): 103-111.

Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med, 2001, 345: 1667-1675.

Pfeffer MA, Swedberg K, Granger CB, CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003, 362(9386): 759-66, 1667-1675.

McMurray JJ, Ostergren J, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function. taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 2003, 362(9386): 767-771.

Gu J, Noe A, Chandra P et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol, 2010, 50: 401-414.

Hegde LG, Yu C, Renner T et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol, 2011, 57: 495-504.

Ruilope LM, Dukat A, Buhm M et al. Blood pressure reduction with LCZ696, a novel dual acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet, 2010, 375: 1255-1266.

Solomon SD, Zile M, Pieske B et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, 2012, 380(9851): 1387-1395.

McMurray JJ, Packer M, Desai AS et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med, 2014, 371: 993-1004.

http://www.escardio.org/about/press/press-releases/pr-14/Pages/paradigm-hf-trial-stopped-early-for-benefit.aspx.http://www.escardio.org/about/press/press-releases/pr-14/Pages/paradigm-hf-trial-stopped-early-for-benefit.aspx

Desai AS, Vardeny O, Claggett B et al. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol, 2017 Jan 1, 2(1): 79-85.

Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность, 2013, 81(7): 379-472.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail, 2016, 18(8): 891-975.

Seferovic JP, Claggett B, Seidelmann SB et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol, 2017 May, 5(5): 333-340.

EMA, New medicine to treat heart failure recommended for approval. Available at: http:// www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Public_assessment_report/ human/ 004062/WC500197538.pdf.http://www.ema.europa.eu/docs/en_GB/document_

FDA. FDA approves new drug to treat heart failure. Available at: www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm453845. htm.www.fda.gov/NewsEvents/

https://www.rlsnet.ru/mnn_index_id_6718.htm.https://www.rlsnet.ru/mnn_index_id_6718.htm

Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart, 2016, 102(17): 1342-1347.

Дополнительная информация
Язык текста: Русский
ISSN: 2079-701X
Унифицированный идентификатор ресурса для цитирования: //medj.rucml.ru/journal/4e432d4d4544534f5645542d41525449434c452d323031372d302d31322d302d3131322d313137/